sivelestat sodium hydrate
ApprovedSmall molecule
Ono Pharmaceutical Co. Ltdsivelestat sodium hydrate is one of 15 small molecule programs targeting Systemic Inflammatory Response Syndrome. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Systemic Inflammatory Response Syndrome
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Thalomid
Bristol-Myers SquibbPhase 3
Ilaris
NovartisPhase 3
Dexamethasone Phosphate
EEyegate Pharmaceuticals, Inc.
Approved
Albumin
LLaboratoire français de Fractionnement et de Biotechnologies
Approved
Solumedrol
SStanford University
Approved
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Phase 3
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Phase 3
Yescarta
GileadPhase 2
sivelestat sodium hydrate
Ono Pharmaceutical Co. LtdApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sivelestat sodium hydrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company